As reported, PTEN deletion influences the disease progression of both CML and B-ALL by regulating its downstream target Akt1 [21], through which the BCR-ABL fusion gene regulates ABCG2 expression [28]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.